Pharmacoeconomic Evaluation of Drug Brands for Angina Pectoris and Decompensated Cardiomyopathy in Tertiary Care Teaching Hospitals

Abstract

Background: Pharmacoeconomics is a specialized branch of health economics that evaluates the costs and benefits associated with drug therapy, guiding resource allocation and planning in healthcare. The World Health Organization emphasizes the importance of understanding drug utilization, including its marketing, distribution, prescription, and societal impacts. Effective therapeutic practice relies on evidence from pre-marketing clinical trials, although supplementary post-marketing data are crucial for informed drug therapy implementation.

Objective: This study aims to conduct a pharmacoeconomic evaluation of various brands of drugs used in the treatment of angina pectoris and decompensated cardiomyopathy in a tertiary care setting.

Methods: A prospective observational study was conducted in the cardiology ward of Narayana Hospitals, Nellore, over a two-year period. A total of 300 patients with angina pectoris and decompensated cardiomyopathy were assessed, with 250 patients meeting the inclusion criteria. Inclusion criteria encompassed patients aged 30 to 60 years, with various types of angina and decompensated cardiomyopathy, co-morbid conditions, a history of heart complaints, and willingness to participate. Exclusion criteria included pregnant women, those unwilling to provide information, pediatric patients, individuals with poor verbal communication, and unconscious patients. The study utilized an informed consent form and a specially designed quality of life (QOL) questionnaire.

Results: The findings from this study will provide valuable insights into the economic implications of drug therapy for angina pectoris and decompensated cardiomyopathy, highlighting potential benefits for patients and informing healthcare decision-makers.